Abstract: The pharmaceutical business is transitioning to a more sustainable model, with a great-er emphasis on next-generation and green excipients to improve medicine formulation while re-ducing environmental impact. However, incorporating these innovative excipients into pharma-ceutical development presents regulatory uncertainty, safety concerns, and compliance issues. This analysis delves into the growing regulatory framework governing next-generation excipients, emphasizing the difficulties of toxicological examination, approval routes, and worldwide regula-tory agency harmonization initiatives. The article discusses the scientific advances that are driv-ing the development of green excipients, including biodegradable polymers, plant-derived stabi-lizers, and biocompatible nanocarriers, as well as their safety profiles, biopharmaceutical perfor-mance, and scalability. It also examines regulatory challenges such as the lack of standardized evaluation frameworks, the necessity for in vitro and in silico risk assessment models, and the importance of Good Manufacturing Practices (GMP) and regulatory filings in assuring compli-ance. Furthermore, this study assesses the balance between innovation and regulation, arguing that the desire for environmentally friendly pharmaceutical excipients must be balanced with se-vere safety and effectiveness criteria. The possibility for regulatory change, collaborative industry efforts, and AI-driven predictive toxicity is also investigated as a significant facilitator for speed-ing up next-generation excipient approval. As the pharmaceutical industry adopts green chemistry concepts, bridging the gap between innovation and regulatory compliance will be critical for long-term medication development. This paper discusses how to overcome present hurdles and establish a proactive regulatory environment that promotes the safe and efficient use of next-generation excipients.
Kolay et al. (2025) studied this question.